Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Pharmaceutical Holding Ltd (NY: BHVN )

151.76 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 151.76
Bid (Size) 126.13 (1)
Ask (Size) 152.24 (10)
Prev. Close 151.76
Today's Range 151.76 - 151.76
52wk Range 79.01 - 152.13
Shares Outstanding 65,401,228
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Stocks That Hit 52-Week Highs On Friday
  On Friday, 5 companies hit new 52-week highs. 
Via Benzinga
Watch for Continued Gains in Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Via Investor Brand Network

Performance

YTD
+9.05%
+9.05%
1 Month
+2.02%
+2.02%
3 Month
+5.38%
+5.38%
6 Month
+29.18%
+29.18%
1 Year
+14.21%
+14.21%

More News

Read More
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
Via Investor's Business Daily
Is Viatris Inc. a Contrarian Dividend Option for Your Portfolio?
Via MarketBeat
Recap: Biohaven Pharma Hldgs Q2 Earnings
Via Benzinga
Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study
Via Benzinga
Biohaven Pharmaceutical's Return On Capital Employed Overview
Via Benzinga
$5.6 Million Bet On This Healthcare Stock? 3 Stocks Insiders Are Buying
Via Benzinga
Freedom Biosciences Gets $10.5M In Seed Financing For Psychedelics Research, This Is What We Know
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2022
Via Benzinga
Why These Pfizer Analysts Like The Global Blood Therapeutics Deal
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
Via Benzinga
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion
Via Investor's Business Daily
The 3 Best Market Sectors for the Second Half of 2022
Via InvestorPlace
Which Coronavirus Stock Could Fetch Higher Returns?
Via InvestorPlace
Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
From Global Coalition for Adaptive Research
Via Business Wire
Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit?
Via Investor's Business Daily
Hopeful Golden Cross Forms On Biohaven Pharma Hldgs's Chart
Via Benzinga
Looking Into Biohaven Pharmaceutical's Return On Capital Employed
Via Benzinga
3 Biotech Stocks to Buy Before They Boom
Via InvestorPlace
Pfizer's Nearly $7 Billion Acquisition Of Arena Pharma Just Paid Off In A Big Way
Via Investor's Business Daily
BIOHAVEN INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Biohaven Pharmaceutical Holding Company Ltd. - BHVN
From Kahn Swick & Foti, LLC
Via Business Wire
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Via Benzinga
Stock Market Tries To Bounce From Fresh 2022 Lows; Tesla CEO Elon Musk Puts Twitter Deal 'On Hold': Weekly Review
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.